Last updated: November 11, 2026
Midostaurin, marketed by Novartis as Rydapt, is a targeted kinase inhibitor with two approved commercial uses: newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and advanced systemic mastocytosis. Global sales have remained broadly stable at roughly $0.5 billion annually, supported by a specialized AML population and continued use in advanced systemic mastocytosis. The principal commercial risks are competition from gilteritinib and quizartinib in FLT3-mutated AML, avapritinib in systemic mastocytosis, and eventual generic entry after regulatory and patent barriers weaken.
What is midostaurin used for and how does Rydapt generate revenue?
Midostaurin is an oral multikinase inhibitor that targets FLT3, KIT, and other kinases. Rydapt is approved in the United States for:
- Newly diagnosed AML in adults whose blasts have a FLT3 mutation, used with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy.
- Adults with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia.
The AML indication is commercially important because it places Rydapt in the front-line treatment pathway. The drug is used with chemotherapy rather than as a stand-alone regimen, which limits total treatment duration but anchors use at diagnosis.
The systemic mastocytosis indication has a smaller patient population and a more chronic treatment pattern. Patients with advanced disease may receive treatment for longer periods, increasing revenue per patient. That benefit is constrained by competition from more selective KIT inhibitors.
| Metric |
Assessment |
| Active ingredient |
Midostaurin |
| Brand |
Rydapt |
| Originator |
Novartis |
| FDA approval |
April 28, 2017 for FLT3-mutated AML; September 1, 2017 for advanced systemic mastocytosis |
| Drug class |
Oral multikinase inhibitor |
| Main commercial markets |
United States, Europe, Japan and other major oncology markets |
| Primary AML biomarker |
FLT3 mutation |
| Main competing AML drugs |
Gilteritinib, quizartinib and salvage chemotherapy |
| Main systemic mastocytosis competitor |
Avapritinib |
| Product type |
Small molecule; biosimilar substitution does not apply |
The FDA approved Rydapt with companion diagnostic testing for FLT3 mutation status. Novartis relies on a narrow, biomarker-defined AML population rather than broad AML use. The commercial model therefore depends on testing rates, treatment guidelines, diagnosis volumes, and continued physician adoption.
How have midostaurin sales changed over time?
Rydapt sales have followed a mature-product pattern, with annual revenue generally near $0.5 billion rather than showing the rapid growth associated with a newly launched oncology medicine.
Reported Novartis product sales were approximately:
| Year |
Rydapt sales |
Market interpretation |
| 2020 |
About $0.52 billion |
Established AML and systemic mastocytosis demand |
| 2021 |
About $0.53 billion |
Stable use despite competitive entry |
| 2022 |
About $0.55 billion |
Resilient demand in both indications |
| 2023 |
About $0.55 billion |
Mature, broadly flat revenue profile |
| 2024 |
Approximately $0.5 billion range |
Continued commercial durability, with competition limiting growth |
Figures are rounded and reflect Novartis reported product sales, not publicly disclosed revenue by indication. Novartis reports Rydapt as a product rather than publishing separate revenue for AML and systemic mastocytosis in its standard financial statements (Novartis, 2021, 2022, 2023, 2024).
The financial trajectory has three defining characteristics:
- AML provides volume and guideline-driven demand.
- Systemic mastocytosis provides a smaller but potentially longer-duration treatment base.
- Competitive products limit price and volume expansion.
Rydapt is no longer a high-growth asset. Its value is closer to that of a durable specialty oncology franchise with moderate revenue concentration and a relatively defensible clinical position.
What factors are supporting Rydapt revenue?
How does the AML indication support demand?
The RATIFY trial established the clinical basis for adding midostaurin to standard induction and consolidation chemotherapy in newly diagnosed FLT3-mutated AML. The trial showed improved overall survival compared with chemotherapy alone, supporting incorporation into treatment guidelines and regulatory approvals (Stone et al., 2017).
Demand benefits from several factors:
- FLT3 mutations occur in roughly one-quarter to one-third of AML cases.
- Patients are routinely tested for FLT3 at diagnosis.
- Rydapt is embedded in a front-line regimen rather than reserved only for relapsed disease.
- The treatment has long-standing physician familiarity.
- The product is available across multiple major oncology markets.
The main limitation is that Rydapt is not used in all AML patients. It is restricted to FLT3-mutated disease and is most relevant to patients fit for intensive chemotherapy. Older or medically frail patients may receive lower-intensity regimens, reducing the addressable population.
How does systemic mastocytosis support revenue?
The systemic mastocytosis indication gives Rydapt access to a rare-disease population with high unmet need. Advanced systemic mastocytosis is associated with organ damage, aggressive disease biology and poor prognosis. Midostaurin demonstrated activity across advanced systemic mastocytosis subtypes and became an important treatment option after approval (Gotlib et al., 2016).
This indication has favorable revenue characteristics:
- Disease severity can support specialty-drug pricing.
- Treatment may continue longer than a defined AML chemotherapy course.
- Diagnosis often occurs through specialist hematology centers.
- Patient management is concentrated, which can support targeted commercial infrastructure.
The main pressure is avapritinib, a more selective KIT D816V inhibitor with approvals spanning advanced and indolent systemic mastocytosis. Avapritinib has a stronger mechanistic fit for KIT-driven disease and can compete directly for advanced systemic mastocytosis patients.
How does Rydapt compare with competing FLT3 inhibitors?
Rydapt remains strongest in newly diagnosed FLT3-mutated AML treated with intensive chemotherapy. Its position is less secure in relapsed or refractory disease, where other FLT3 inhibitors have stronger labels or more direct clinical use.
| Drug |
Company |
Primary AML position |
Competitive effect on Rydapt |
| Rydapt, midostaurin |
Novartis |
Newly diagnosed FLT3-mutated AML with chemotherapy |
Established front-line standard |
| Xospata, gilteritinib |
Astellas |
Relapsed or refractory FLT3-mutated AML |
Limits Rydapt in later-line use |
| Vanflyta, quizartinib |
Daiichi Sankyo |
Newly diagnosed FLT3-ITD-positive AML with chemotherapy |
Direct front-line competitor |
| Ayvakit, avapritinib |
Bristol Myers Squibb |
Advanced and indolent systemic mastocytosis |
Direct systemic mastocytosis competitor |
Quizartinib is the most important newer AML competitor because it entered the same general front-line FLT3-mutated AML setting. The FDA approved quizartinib in 2023 for adults with newly diagnosed AML that is FLT3-ITD positive, in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, followed by maintenance monotherapy in eligible patients (FDA, 2023).
The competitive distinction is clinically relevant:
- Midostaurin covers FLT3 mutations broadly within its approved setting.
- Quizartinib focuses on FLT3-ITD-positive disease.
- Gilteritinib is primarily positioned in relapsed or refractory FLT3-mutated AML.
- Treatment selection depends on mutation subtype, chemotherapy fitness, transplant strategy, institutional protocols and reimbursement.
The arrival of quizartinib creates the clearest risk to Rydapt’s AML growth. It does not automatically eliminate Rydapt demand because the products have different data packages, labels, mutation coverage and physician adoption patterns.
What is the FDA regulatory status and exclusivity position of Rydapt?
Rydapt has full FDA approval in two orphan oncology indications. The FDA approval history is:
| Date |
Regulatory event |
| April 28, 2017 |
Approval for newly diagnosed FLT3-mutated AML with chemotherapy |
| September 1, 2017 |
Approval for advanced systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia |
| 2023 |
Continued FDA-approved use as a front-line AML option while quizartinib entered the market |
The seven-year orphan-drug exclusivity periods attached to the 2017 approvals would generally have ended in 2024, subject to indication-specific regulatory treatment and any applicable pediatric extension. Orphan exclusivity prevents FDA approval of the same drug for the same indication during the exclusivity period, but it does not block all competing products.
Rydapt is a small molecule, so it does not receive the 12-year biologic exclusivity framework or face biosimilar competition. Future competition would come through abbreviated new drug applications for generic midostaurin, subject to patent, regulatory and formulation barriers.
What patents protect midostaurin and when could generic entry occur?
Rydapt protection has several potential layers:
- The active ingredient and chemical composition.
- Pharmaceutical formulations and oral dosage forms.
- Methods of treating FLT3-mutated AML.
- Methods of treating advanced systemic mastocytosis.
- Regulatory exclusivity linked to orphan indications.
- Possible pediatric exclusivity or patent-term adjustment.
The original chemical matter is older than the 2017 FDA approvals. Commercial protection therefore depends more heavily on later formulation, dosing and method-of-use rights than on the original compound patent.
The U.S. Orange Book should be used to identify live listed patents and their exact expiration dates. Public patent records associate Rydapt with later-issued midostaurin patents that can extend protection beyond the original chemical patent, with certain rights reported into the late 2020s or around 2030 depending on the patent, jurisdiction and applicable adjustments (FDA, 2024; USPTO, 2024).
A practical entry framework is:
| Period |
Generic-entry risk |
| Before 2024 |
Limited by orphan exclusivity and listed patent rights |
| 2024 onward |
Orphan exclusivity barrier begins to fall away |
| Late 2020s |
Risk increases as later patents approach expiry or are challenged |
| Around 2030 |
Potentially material U.S. generic exposure, subject to patent litigation and FDA approval timing |
No biosimilar risk exists because midostaurin is not a biologic. Generic risk is more likely to emerge through paragraph IV patent challenges than through a biosimilar pathway.
Which companies are challenging Rydapt exclusivity?
Publicly disclosed commercial activity around Rydapt has centered more on competitive product launches than on a widely documented, mature generic litigation campaign. Generic manufacturers could challenge listed patents through paragraph IV certifications, but the business case depends on:
- The remaining patent term.
- The ability to demonstrate bioequivalence for the capsule formulation.
- The commercial value of the AML and systemic mastocytosis indications.
- The cost of patent litigation.
- The potential for a first-filer 180-day generic exclusivity period.
- Whether a generic applicant can carve out patented methods of use.
A generic applicant may seek approval for non-patented indications while using a skinny label to exclude protected methods. That strategy could be difficult for Rydapt if the principal commercial value is concentrated in the same indications covered by method-of-use patents.
No confirmed Rydapt settlement terms with a major generic challenger are reflected in the cited public sources. This limits the ability to assign a specific authorized-generic launch date or settlement-based entry date.
How strong is the midostaurin patent estate?
Rydapt has a moderate commercial patent position rather than a classic long-life composition-of-matter estate.
Strengths include:
- Multiple indications with separate regulatory histories.
- Specialized oncology use that makes clinical substitution more difficult than simple tablet substitution.
- Potential method-of-use protection.
- A technically defined patient population requiring diagnostic confirmation.
- High switching costs in established AML treatment pathways.
Weaknesses include:
- The underlying molecule is not new.
- The FDA orphan-exclusivity period has ended.
- Several competing FLT3 inhibitors are already approved.
- Generic applicants may challenge formulation or method patents.
- The product has no biologic exclusivity.
- AML treatment is increasingly segmented by FLT3 subtype and treatment fitness.
The commercial durability of Rydapt therefore depends on patent enforcement, physician familiarity, guideline persistence and the ability to retain share against quizartinib and gilteritinib.
What litigation and settlement risks affect Rydapt?
The principal legal risks are likely to involve:
- Paragraph IV challenges to listed U.S. patents.
- Declaratory-judgment actions over method-of-use or formulation claims.
- Patent-term and pediatric-extension disputes.
- Carve-out labeling disputes.
- Competition between Rydapt and newer targeted AML products.
A generic litigation event could accelerate valuation pressure even before commercial launch. Investors typically revalue mature oncology products when a credible first filer identifies a viable path to market, especially if the product has a concentrated revenue base and limited post-launch growth.
No confirmed settlement agreement is identified in the cited sources that establishes an authorized generic or a fixed Rydapt entry date. Patent litigation status should therefore be treated as a live diligence item rather than a resolved commercial event.
What is the geographic coverage and international risk?
Novartis sells Rydapt in major oncology markets, including the United States, Europe and Japan. International revenue is affected by:
- National reimbursement decisions.
- Health technology assessment outcomes.
- Regional testing rates for FLT3 and KIT mutations.
- Reference pricing.
- Local patent terms.
- Generic approval timing.
- Differences in AML treatment guidelines.
The United States remains strategically important because of higher oncology pricing and a large concentration of specialty care. Europe provides broad market access but generally carries greater price pressure and country-level reimbursement variation. Japan and other Asian markets contribute additional volume but may have narrower reimbursement criteria.
Patent and generic entry are jurisdiction-specific. A U.S. generic launch would not automatically produce simultaneous entry in Europe, Japan or other markets.
What generic launch scenarios exist for midostaurin?
Three scenarios are commercially relevant.
Scenario 1: Delayed generic entry
Patent litigation or formulation barriers delay launch until the late 2020s or around 2030. Rydapt maintains a stable revenue base, but quizartinib and avapritinib limit growth.
Scenario 2: At-risk launch
A generic manufacturer launches before final resolution of patent litigation. This could produce rapid price erosion and a sharp decline in U.S. revenue if the product is later found to infringe.
Scenario 3: Limited-label generic entry
A generic launches with patented indications carved out. The product may compete in selected uses, while Novartis retains some protected indication share. This outcome could slow, rather than eliminate, Rydapt erosion.
For a mature product with approximately $0.5 billion in global sales, the United States would likely account for a disproportionate share of early revenue loss because of pricing and generic substitution mechanics.
How does Rydapt compare with Ayvakit and Vanflyta commercially?
Rydapt has the advantage of market tenure and established clinical use. Ayvakit and Vanflyta have more recent mechanisms and can target segments where Rydapt is less differentiated.
| Commercial factor |
Rydapt |
Ayvakit |
Vanflyta |
| Core disease area |
AML and advanced systemic mastocytosis |
Systemic mastocytosis |
FLT3-ITD-positive AML |
| Launch maturity |
Mature |
Growth-stage |
Growth-stage |
| Key advantage |
Established front-line AML use |
Selective KIT targeting and broader mastocytosis opportunity |
Direct front-line FLT3-ITD competition |
| Main risk |
Patent and generic erosion |
Safety, reimbursement and market development |
Narrower mutation coverage and adoption barriers |
| Revenue profile |
Stable mature product |
Expansion-oriented |
Newer launch with competitive pressure |
Rydapt’s strongest defense is its entrenched role in FLT3-mutated AML treatment. Its weakest position is systemic mastocytosis, where avapritinib offers a more targeted competitor and may capture treatment share as diagnosis expands.
Key Takeaways
- Midostaurin is a mature specialty oncology product with global annual sales near $0.5 billion.
- Rydapt revenue is supported by front-line FLT3-mutated AML and advanced systemic mastocytosis.
- The AML business is durable but faces direct pressure from quizartinib and indirect pressure from gilteritinib.
- Avapritinib is the main competitive threat in systemic mastocytosis.
- The seven-year orphan exclusivity periods from the 2017 approvals have generally expired.
- Rydapt is exposed to generic, not biosimilar, competition.
- Later patents and method-of-use claims may delay U.S. generic entry into the late 2020s or around 2030.
- No cited public source establishes a definitive Rydapt generic launch date or settlement-based entry date.
- Revenue is likely to remain stable before generic entry, with limited growth potential.
- A successful paragraph IV challenge would create the largest near-term valuation risk.
FAQs About Midostaurin Market Dynamics
Is midostaurin still a standard treatment for FLT3-mutated AML?
Yes. Midostaurin remains an approved front-line option for newly diagnosed FLT3-mutated AML when used with intensive induction and consolidation chemotherapy.
Does midostaurin have biosimilar competition?
No. Midostaurin is a small-molecule drug, so any future competition would come from generic versions rather than biosimilars.
Which drug competes most directly with Rydapt in AML?
Quizartinib is the most direct newer competitor in newly diagnosed FLT3-ITD-positive AML. Gilteritinib competes more strongly in relapsed or refractory FLT3-mutated AML.
Which drug competes most directly with Rydapt in systemic mastocytosis?
Avapritinib is the principal direct competitor, particularly because of its selective KIT activity and systemic mastocytosis indications.
What would cause Rydapt sales to decline sharply?
The most likely causes are an approved generic, an at-risk generic launch, loss of front-line AML share to quizartinib, or accelerated displacement in systemic mastocytosis by avapritinib.
References
-
Food and Drug Administration. (2023). FDA approves quizartinib with chemotherapy for newly diagnosed acute myeloid leukemia. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2017). Rydapt prescribing information. U.S. Department of Health and Human Services.
-
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., et al. (2016). Efficacy and safety of midostaurin in advanced systemic mastocytosis. New England Journal of Medicine, 374(26), 2530-2541.
-
Novartis. (2021). Annual report 2021. Novartis AG.
-
Novartis. (2022). Annual report 2022. Novartis AG.
-
Novartis. (2023). Annual report 2023. Novartis AG.
-
Novartis. (2024). Annual report 2024. Novartis AG.
-
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., et al. (2017). Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England Journal of Medicine, 377(5), 454-464.
-
United States Patent and Trademark Office. (2024). Patent Center and patent term information. U.S. Department of Commerce.